Trial Profile
Randomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Dec 2022
Price :
$35
*
At a glance
- Drugs Zoptarelin doxorubicin (Primary) ; Doxorubicin
- Indications Adenocarcinoma; Endometrial cancer
- Focus Registrational; Therapeutic Use
- Acronyms ZoptEC
- Sponsors AEterna Zentaris Inc
- 09 Dec 2022 Results assessing dostarlimab (n = 92) efficacy and safety from the single-arm GARNET (NCT02715284) trial compared with doxorubicin ((n = 233) from ZoptEC (NCT01767155) published in the Oncologist
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 01 May 2017 Results published in an Aeterna Zentaris media release.